Bruce Booth Sells Shares of Kymera Therapeutics
Bruce Booth sold 115,056 shares of Kymera Therapeutics, valued at $10.47 million, on June 18, 2026.
Key Points
- Bruce Booth sold 115,056 shares of Kymera Therapeutics on June 18, 2026, for a total value of $10.47 million.
- Kymera Therapeutics, trading at $99.45 on Tuesday, has a market cap of $8.18 billion and a forward P/E of -22.89.
- FMR LLC increased its holding in Kymera by 2,771,376 shares, while T. Rowe Price Investment Management added 4,835,252 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Bruce Booth sold 115,056 shares of Kymera Therapeutics, Inc. (NasdaqGM:KYMR) on June 18, 2026. The shares were sold at an average price of $91.01 each, totaling approximately $10.47 million. This transaction was planned in advance.
Insider Buying and Selling at Kymera Therapeutics, Inc.
In addition to Bruce Booth's transaction, several other insiders have been active at Kymera Therapeutics. On June 22, 2026, Noah Goodman, the Chief Business Officer, sold 2,500 shares at $99.00 each under a pre-planned arrangement. On the same day, he also bought 2,500 shares at $21.05. Bruce Booth made another planned sale of 278,128 shares at $99.12 on June 22, 2026.
Other Institutional Activity in Kymera Therapeutics
Institutional investors have also been making moves in Kymera Therapeutics. FMR LLC increased its holdings by 2,771,376 shares, ending with a total of 11,699,950 shares valued at about $974.49 million. T. Rowe Price Investment Management, Inc. added 4,835,252 shares, bringing its total to 5,464,997 shares worth approximately $455.18 million. Meanwhile, Price T Rowe Associates Inc /MD/ reduced its stake by 98,488 shares, holding 6,060,847 shares valued at $504.81 million.
Kymera Therapeutics, Inc. Stock Down 15.8%
Shares of Kymera Therapeutics traded near $99.45 on Tuesday. The company has a market cap of $8.18 billion and a forward P/E ratio of -22.89, indicating it is not currently profitable. Its beta of 2.027 suggests higher volatility compared to the market. The stock's 52-week range is between $36.65 and $105.00, with a 50-day moving average of $83.06 and a 200-day moving average of $73.55. Kymera maintains a strong liquidity position with a current ratio of 10.814 and a quick ratio of 10.391.
$KYMR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Several analysts have recently updated their price targets for Kymera Therapeutics. On May 6, 2026, Canaccord Genuity initiated coverage with a 'buy' rating and a price target of $106. UBS maintained its 'buy' rating with a target of $128 on March 3, 2026. The consensus among 21 analysts is a 'strong buy' with a mean target price of $119.19.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it focuses on developing small molecule therapeutics that target and degrade disease-causing proteins. The company's pipeline includes treatments for a variety of conditions, including autoimmune diseases and oncology. Kymera has a strategic partnership with Sanofi S.A. for developing drug candidates targeting IRAK4 outside oncology fields. The company is led by CEO Dr. Nello Mainolfi and employs 253 people.
Bottom Line
Bruce Booth's recent sale of Kymera Therapeutics shares is part of a planned transaction and reflects ongoing insider activity at the company. Kymera's stock is closely watched for its innovative approach in the biotechnology sector. Investors should note that the information from 13F filings and insider transactions is historical and may not represent current positions.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.